BrainsWay Ltd. Announces That The Clinical TMS Society Publishes First Coverage Recommendations For The Treatment Of Smoking Addiction
Portfolio Pulse from Benzinga Newsdesk
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced that the Clinical TMS Society (CTMSS) has published the first coverage recommendations for smoking addiction treatment using transcranial magnetic stimulation (TMS). BrainsWay's Deep TMS is the only TMS technology to have received FDA clearance for the treatment of smoking addiction. The CTMSS now recommends TMS coverage for individuals with a confirmed diagnosis of Tobacco Use Disorder (TUD) who failed two alternative treatment methods, cannot tolerate drugs, or have other comorbid medical conditions.
November 02, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BrainsWay's Deep TMS technology has received coverage recommendations from the CTMSS for the treatment of smoking addiction. This could potentially increase the usage of their technology and boost their revenues.
The coverage recommendations from CTMSS for BrainsWay's Deep TMS technology could lead to increased usage of their technology for the treatment of smoking addiction. This could potentially lead to increased revenues for the company, which would likely have a positive impact on their stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100